Trial Profile
A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tesetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 23 Jul 2012 Additional lead investigator (Tina Mayer) added as reported by ClinicalTrials.gov.
- 11 Mar 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
- 11 Mar 2012 Planned number of patients changed from 96 to 57 as reported by ClinicalTrials.gov.